The Big Problem with Price Controls: Scarcity

One of the most pressing problems facing Americans and the U.S. healthcare system is the affordability of prescription drugs. An estimated 58 million Americans face medication insecurity and have “been unable to afford prescribed drugs at least once in the last 12 months.” The Organization for Economic Co-Operation and Development claimed that per capita, Americans pay $1,220 per year […]

Real Clear Policy: Are ‘Affordability Boards’ the Answer to Increasing Drug Prices?

A growing number of states are looking to set up prescription drug affordability review boards to reel in soaring prescription drug prices. In most cases, the proposed boards would allow the states to set pricing caps for certain higher-cost drugs, as well as limit price increasing by drug makers. Yet, contrary to expectations, a new […]

The Hill: Competition, Not Capping Increases, is the Cure for High Drug Prices

Soaring prescription drug prices are putting financial pressure on families across the country. In response, state legislators are increasingly considering limits on the annual price increase of prescription drugs. But rather than making drugs more affordable, these policies risk reducing consumer access to cheaper, generic alternatives. Read this op-ed in The Hill       […]

Real Clear Health: Rx Price Transparency Is Key to Lowering Health Care Costs

The Trump administration’s recent efforts to increase transparency in hospital pricing have expectedly been met with legal push-back from the hospitals themselves. But shadowy hospital pricing is just the tip of the opaque iceberg that is driving up the costs of health care in America. To inject more competition into the industry, Congress and the […]

ACI Joins Coalition in Opposition to the Pelosi Drug Tax Pan

Today, ACI joined 70 other organizations in opposition to the prescription drug pricing bill offered by House Speaker Nancy Pelosi. The bill would impose excise taxes up to 95% on hundreds of prescription medicines. You can read the coalition letter online. 10-15-19 Coalition Letter Opposed to Pelosi Drug Tax Plan

Counterfeits Kill: Stronger Law Enforcement Needed

When one thinks of counterfeit goods, it can conjure up images of customers being duped into buying inferior quality designer bags or other fashion knockoffs. However, when it comes to the manufacturing, distribution and sale of counterfeit medications, the outcomes can be much more serious and life threatening. Most consumers probably don’t realize that counterfeit […]

Latest ConsumerGram: Lowering Drug Prices in Maryland Means Bringing Transparency to PBMs

Pharmacy Benefit Managers (PBMs) administer prescription drug plans for sponsors (e.g., employers and insurers), negotiate drug prices with manufacturers, and negotiate reimbursement terms with pharmacies. This ConsumerGram analyzes the structure, conduct and performance of the industry and finds that the lack of transparency in costs and prices leads to anticompetitive risks. The result can mean […]

Inside Sources: Pharmacy Benefit Managers Pad Their Profits at Your Expense

The harmful and anti-competitive business practices that PBMs thrive on are made possible by the industry’s secrecy and lack of transparency. Plan sponsors and beneficiaries should be given more information about how their insurance plans are managed and what rates are negotiated. Pharmacies should be allowed, and even encouraged, to point customers to lower-cost alternatives […]

Prescription Drugs That Your Insurer Objects to Paying For

Consumers have a love-hate relationship with prescription drugs.  We love the wonderful new drugs that treat and sometimes cure conditions that were once life-threatening, but we hate the sometimes-unaffordable prices of the latest drugs.  Consumers who have prescription insurance coverage are somewhat insulated from the full price of drugs, but insurers and pharmacy benefit managers […]

Can Drug Prices be Lowered?

Lowering the consumer price for a drug is in the public interest, provided that its sales margin recovers its development cost.  Pharmaceuticals do not spontaneously emerge like weeds in a field.  They are complex chemical or biological agents that are painstakingly designed and extensively tested for safety and efficacy.   That said, there are steps worth […]